Controlled trial of high-dose octreotide in treatment of acute pancreatitis. Evidence of improvement in disease severity.
Nineteen consecutive patients with acute pancreatitis were sequentially allocated to treatment with high-dose octreotide (N = 9) or to act as controls (N = 10). All other aspects of treatment were similar and were according to a strict treatment protocol. There was no significant difference between the two groups on admission with regard to recognized criteria of poor prognosis. The octreotide-treated group required significantly less analgesia and after 48 hr developed significantly fewer poor prognostic indicators, including falls in hematocrit of > 10%, in serum albumin to < 32 g/liter, and in serum calcium to < 2.00 mmol/liter. Falls in arterial PO2 to < 10 kPa, in serum albumin of > 20%, and in hemoglobin of > 2 g/dl were also significantly less frequent. There was a trend towards improvement in the octreotide-treated group in every other physiological and radiological indicator of disease severity. High-dose octreotide may reduce the severity of acute pancreatitis.
Beechey-Newman
N
N
Department of Surgery, Wycombe General Hospital, Buckinghamshire, England.
D000208:Acute Disease; D003131:Combined Modality Therapy; D006801:Humans; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage*; D010195:Pancreatitis / Q000097:blood / Q000188:drug therapy*; D011379:Prognosis; D012074:Remission Induction; D012720:Severity of Illness Index
D015282:Octreotide